Two New TRU™ Brand Rapid Tests for the Detection of Epstein-Barr Virus

Meridian Bioscience, Inc. has announced the launch of two new rapid tests for Epstein-Barr Virus (EBV): TRU EBV-M™ and TRU EBV-G™. The TRU EBV tests are the first rapid tests on the market which employ recombinant antigen technology to detect IgM and IgG antibodies specific to EBV.

EBV is the primary cause of infectious mononucleosis and has been implicated in a number of benign and malignant disorders, including Hodgkin's disease and certain lymphomas. According to the Centers for Disease Control and Prevention (CDC), as many as 95% of adults ages 35-40 have been infected with EBV.

The current rapid methods for the diagnosis of infectious mononucleosis rely primarily on the patient's symptoms and non-specific heterophile antibody testing. The TRU EBV tests, however, are highly sensitive for specific antibodies that can classify acute and chronic stages of the disease.

The TRU EBV test system is a simple, sensitive and rapid approach that allows healthcare providers to more precisely diagnose EBV infections.

NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source : Meridian Bioscience, Inc. View Company Information

Posted on April 15, 2008








Get our eNewsletter
Over 6,000 microbiology professionals get our weekly eNewsletter - subscribe now and find out why!

LATEST MICROBIOLOGY NEWS

MICROBIOLOGY EVENTS